Proteomic Patterns of Colonic Mucosal Tissues Delineate Crohn's Colitis and Ulcerative Colitis

Overview

Journal Proteomics Clin Appl

Specialty Biochemistry

Date 2013 Feb 6

PMID 23382084

Citations 33

Authors

Erin H Seeley

Mary K Washington

Richard M Caprioli

Amosy E MKoma

Affiliations

Soon will be listed here.

Abstract

Purpose: Although Crohn's colitis (CC) and ulcerative colitis (UC) share several clinical features, they have different causes, mechanisms of tissue damage, and treatment options. Therefore, the accurate diagnosis is of paramount importance in terms of medical care. The distinction between CC/UC is made on the basis of clinical, radiologic, endoscopic, and pathologic interpretations but cannot be differentiated in up to 15% of inflammatory bowel disease patients. Correct management of this "indeterminate colitis" depends on the accuracy of future, and yet not known, destination diagnosis (CC/UC).

Experimental Design: We have developed a proteomic methodology that has the potential to discriminate between UC/CC. The histologic layers of 62 confirmed UC/CC tissues were analyzed using MALDI-MS for proteomic profiling.

Results: A Support Vector Machine algorithm consisting of 25 peaks was able to differentiate spectra from CC and UC with 76.9% spectral accuracy when using a leave-20%-out cross-validation. Application of the model to the entire dataset resulted in accurate classification of 19/26 CC patients and 36/36 UC patients when using a 2/3 correct cutoff. A total of 114 peaks were found to have Wilcoxin rank sum p-values of less than 0.05.

Conclusion And Clinical Relevance: This information may provide new avenues for the development of novel personalized therapeutic targets.

Citing Articles

Integration and implementation of precision medicine in the multifaceted inflammatory bowel disease.

Jagirdhar G, Perez J, Perez A, Surani S World J Gastroenterol. 2023; 29(36):5211-5225.

PMID: 37901450 PMC: 10600960. DOI: 10.3748/wjg.v29.i36.5211.

Ubiquitous Colonic Ileal Metaplasia Consistent with the Diagnosis of Crohn's Colitis among Indeterminate Colitis Cohorts.

Breaux W, Bragg M, MKoma A Med Res Arch. 2023; 11(8).

PMID: 37854669 PMC: 10584353. DOI: 10.18103/mra.v11i8.4188.

The Multifactorial Etiopathogeneses Interplay of Inflammatory Bowel Disease: An Overview.

MKoma A Gastrointest Disord (Basel). 2023; 1(1):75-105.

PMID: 37577036 PMC: 10416806. DOI: 10.3390/gidisord1010007.

Inflammatory Bowel Disease-Associated Colorectal Cancer: Translational and Transformational Risks Posed by Exogenous Free Hemoglobin Alpha Chain, A By-Product of Extravasated Erythrocyte Macrophage Erythrophagocytosis.

Bragg M, Breaux W, MKoma A Medicina (Kaunas). 2023; 59(7).

PMID: 37476546 PMC: 10358352. DOI: 10.3390/medicina59071254.

A Current State of Proteomics in Adult and Pediatric Inflammatory Bowel Diseases: A Systematic Search and Review.

Fabian O, Bajer L, Drastich P, Harant K, Sticova E, Daskova N Int J Mol Sci. 2023; 24(11).

PMID: 37298338 PMC: 10253608. DOI: 10.3390/ijms24119386.

References

Shen B, Remzi F, Brzezinski A, Lopez R, Bennett A, Lavery I . Risk factors for pouch failure in patients with different phenotypes of Crohn's disease of the pouch. Inflamm Bowel Dis. 2008; 14(7):942-8. DOI: 10.1002/ibd.20409. View

Shkoda A, Werner T, Daniel H, Gunckel M, Rogler G, Haller D . Differential protein expression profile in the intestinal epithelium from patients with inflammatory bowel disease. J Proteome Res. 2007; 6(3):1114-25. DOI: 10.1021/pr060433m. View

Puri K, Suresh K, Gogtay N, Thatte U . Declaration of Helsinki, 2008: implications for stakeholders in research. J Postgrad Med. 2009; 55(2):131-4. DOI: 10.4103/0022-3859.52846. View

Maser E, Villela R, Silverberg M, Greenberg G . Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol. 2006; 4(10):1248-54. DOI: 10.1016/j.cgh.2006.06.025. View

Travis S, Farrant J, Ricketts C, Nolan D, Mortensen N, Kettlewell M . Predicting outcome in severe ulcerative colitis. Gut. 1996; 38(6):905-10. PMC: 1383200. DOI: 10.1136/gut.38.6.905. View

Chaurand P, Schwartz S, Billheimer D, Xu B, Crecelius A, Caprioli R . Integrating histology and imaging mass spectrometry. Anal Chem. 2004; 76(4):1145-55. DOI: 10.1021/ac0351264. View

Keighley M . The final diagnosis in pouch patients for presumed ulcerative colitis may change to Crohn's disease: patients should be warned of the consequences. Acta Chir Iugosl. 2001; 47(4 Suppl 1):27-31. View

Ullman T, Itzkowitz S . Intestinal inflammation and cancer. Gastroenterology. 2011; 140(6):1807-16. DOI: 10.1053/j.gastro.2011.01.057. View

Kader H, Tchernev V, Satyaraj E, Lejnine S, Kotler G, Kingsmore S . Protein microarray analysis of disease activity in pediatric inflammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol. 2005; 100(2):414-23. PMC: 1586185. DOI: 10.1111/j.1572-0241.2005.40819.x. View

10.

Gisbert J, Bermejo F, Perez-Calle J, Taxonera C, Vera I, McNicholl A . Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis. 2009; 15(8):1190-8. DOI: 10.1002/ibd.20933. View

11.

Cornett D, Mobley J, Dias E, Andersson M, Arteaga C, Sanders M . A novel histology-directed strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics. 2006; 5(10):1975-83. DOI: 10.1074/mcp.M600119-MCP200. View

12.

Sandborn W, Loftus Jr E, Colombel J, Fleming K, Seibold F, Homburger H . Evaluation of serologic disease markers in a population-based cohort of patients with ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 2001; 7(3):192-201. DOI: 10.1097/00054725-200108000-00003. View

13.

Tibble J, Sigthorsson G, Bridger S, Fagerhol M, Bjarnason I . Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000; 119(1):15-22. DOI: 10.1053/gast.2000.8523. View

14.

Chaurand P, DaGue B, Pearsall R, Threadgill D, Caprioli R . Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics. 2001; 1(10):1320-6. DOI: 10.1002/1615-9861(200110)1:10<1320::AID-PROT1320>3.0.CO;2-G. View

15.

Burczynski M, Peterson R, Twine N, Zuberek K, Brodeur B, Casciotti L . Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn. 2006; 8(1):51-61. PMC: 1867573. DOI: 10.2353/jmoldx.2006.050079. View

16.

Um J, MKoma A . Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Tech Coloproctol. 2011; 15(1):7-16. PMC: 4086905. DOI: 10.1007/s10151-010-0664-2. View

17.

Colombel J, Sandborn W, Reinisch W, Mantzaris G, Kornbluth A, Rachmilewitz D . Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010; 362(15):1383-95. DOI: 10.1056/NEJMoa0904492. View

18.

Romberg-Camps M, Dagnelie P, Kester A, Hesselink-van de Kruijs M, Cilissen M, Engels L . Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104(2):371-83. DOI: 10.1038/ajg.2008.38. View

19.

Sidler M, Leach S, Day A . Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children. Inflamm Bowel Dis. 2007; 14(3):359-66. DOI: 10.1002/ibd.20336. View

20.

Bossuyt X . Serologic markers in inflammatory bowel disease. Clin Chem. 2005; 52(2):171-81. DOI: 10.1373/clinchem.2005.058560. View